Marker Therapeutics, Inc. — Director's Dealing 2009

Oct 26, 2009

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2009-06-29

Reporting Person: WILSON GLYNN (Director, Executive Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2009-06-29	Common stock	J	900000	$0.1	Acquired	900000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2009-10-14	Stock Options	$0.97	A	1600000	Acquired	2019-10-14	Common stock (1600000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options	$0.97	2017-06-08	Common stock (40000)	40000	Direct

Footnotes

F1: These shares were issued as part of a larger transaction in which the Issuer converted outstanding debt of approximately $4,137,000 into approximately 3,333,800 shares of common stock.

F2: These stock options were repriced on October 14, 2009 from $2.50 to $0.97.